DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Information source: Allergy and Asthma Center of El Paso
ClinicalTrials.gov processed this data on November 27, 2014
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: Advair HFA MDI 115/21 (Drug); Symbicort 160/4.5 pMDI (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Allergy and Asthma Center of El Paso

Official(s) and/or principal investigator(s):
Rogelio Menendez, MD, Principal Investigator, Affiliation: Allergy and Asthma Center of El Paso

Overall contact:
Rogelio Menendez, MD, Phone: 915-591-2080, Email: rmaacep@swbell.net

Summary

The objectives of this study are to measure Impulse Oscillometry (IOS) in patients with asthma extensively at baseline in patients with mild-to-moderate asthma, treated with as-needed short acting beta agonist only, to measure respiratory resistance and small airway dysfunction accurately and precisely at baseline, from which to measure onset of action of Advair MDI in comparison with that of Symbicort MDI. Initial screening will assess IOS resistance and small airway dysfunction and its response to short acting beta agonist (SABA). Patients will be selected from among those who manifest a 40% improvement in small airway function assessed by IOS low frequency reactance after SABA compared to baseline. After screening, patients will be randomized to receive either Advair or Symbicort; and will be assessed at randomization before and at several intervals after initial dosing, up to 4 hours. Patients will return again 4 weeks after randomization for extended IOS (and spirometry) testing as done at randomization.

Clinical Details

Official title: Onset of Action of Advair HFA 115/21 in Comparison to Symbicort pMDI 160/4.5 Measured by Impulse Oscillometry, IOS.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Integrated low frequency reactance improvement after initial dosing

Secondary outcome:

Frequency-dependence of Resistance (R5-R20) after initial dosing

Model-derived estimates of Large and Small Airway Resistance and Compliance, and their changes after initial dosing

Detailed description: Eligibility criteria include age 12-45 years, with current treatment of asthma with as-needed SABA only; and manifesting an acute response to SABA at screening of 40% or greater improvement in IOS low frequency reactance. After inclusion in the protocol, all subjects will receive active treatment, either with Advair or with Symbicort. Outcome measures will include large and small airway resistance and integrated low-frequency reactance calculated directly from IOS measures, and in addition, Large Airway Resistance, Small Airway Resistance and Small Airway Compliance derived from an electrical equivalent respiratory system model. Analysis of IOS data will be done post-testing by a respiratory physiologist, experienced with use of IOS and its analysis and interpretation, blinded to which treatment each individual received. Electrical-equivalent respiratory system model analyses will be done by a biomedical engineer, blinded to which treatment each individual received.

Eligibility

Minimum age: 12 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Clinical diagnosis of asthma

- Asthma symptoms controlled by short-acting beta agonist as-needed

- Age 12-45 years

Exclusion Criteria:

- Severe asthma

- use of oral or inhaled corticosteroids within 30 days of screening

Locations and Contacts

Rogelio Menendez, MD, Phone: 915-591-2080, Email: rmaacep@swbell.net

Allergy and Asthma Center of El Paso, El Paso, Texas 79925, United States; Recruiting
Rogelio Menendez, MD, Phone: 915-591-2080, Email: rmaacep@swbell.net
Rogelio Menendez, MD, Principal Investigator
Additional Information

Starting date: September 2008
Last updated: March 23, 2009

Page last updated: November 27, 2014

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014